Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Assets (2020 - 2025)

Historic Assets for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $109.2 million.

  • Barinthus Biotherapeutics' Assets fell 4212.65% to $109.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.2 million, marking a year-over-year decrease of 4212.65%. This contributed to the annual value of $160.3 million for FY2024, which is 2525.76% down from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Assets is $109.2 million, which was down 4212.65% from $129.6 million recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Assets peaked at $286.1 million during Q1 2022, and registered a low of $109.2 million during Q3 2025.
  • Its 5-year average for Assets is $218.4 million, with a median of $230.0 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 45405.01% in 2021, then crashed by 4212.65% in 2025.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Assets stood at $280.7 million in 2021, then fell by 3.74% to $270.2 million in 2022, then dropped by 20.61% to $214.5 million in 2023, then dropped by 25.26% to $160.3 million in 2024, then tumbled by 31.89% to $109.2 million in 2025.
  • Its Assets was $109.2 million in Q3 2025, compared to $129.6 million in Q2 2025 and $142.0 million in Q1 2025.